^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BOS-342

    i
    Other names: BOS-342, PRS-342, lipocalin variant, PRS 342, MPAL1073, BOS342, BOS 342, MPAL 1073, MPAL-1073, PRS342
    Associations

    News

    Trials
    Company:
    Boston Pharma, Palvella Therapeutics
    Drug class:
    CD137 agonist, GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors (ACTRN12623000798662)
    P1/2, N=81, Terminated, Boston Pharmaceuticals, Inc. | Recruiting --> Terminated
    Trial termination
    |
    GPC3 (Glypican 3)
    |
    BOS-342 • methylprednisolone sodium succinate
    over1year
    A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors (ACTRN12623000798662)
    P1/2, N=81, Recruiting, Boston Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    BOS-342
    2years
    A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors (ACTRN12623000798662)
    P1/2, N=81, Not yet recruiting, Boston Pharmaceuticals, Inc.
    New P1/2 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    BOS-342